Cure My Disease

Don't miss your cure!

 Log in / Sign up

Do breast cancer patients stick to their meds? new study aims to find out

NCT ID NCT06650423

Recruiting now Knowledge-focused Sponsor: Institute of Oncology Ljubljana Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow 319 women with early-stage, hormone-sensitive, HER2-negative breast cancer to see how well they take their prescribed aromatase inhibitors, with or without the added drug abemaciclib. Researchers will measure adherence using pill counts and questionnaires at 3 and 6 months. They also want to understand how quality of life, thinking skills, and attitudes toward medication affect adherence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aromatase inhibitors (letrozole, anastrozole, exemestane) with or without abemaciclib
What this could lead to
If successful, this study could reveal why some patients stop taking their breast cancer pills and help doctors improve long-term treatment adherence.
What could go wrong
This is an observational study, not a treatment trial. It will not test whether the drugs work better or worse, only how consistently patients take them.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY BREAST CANCER HER2-NEGATIVE BREAST CANCER HORMONE RECEPTOR POSITIVE TUMOR

Contacts and locations

Locations

  • Institute of Oncology Ljubljana

    RECRUITING

    Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.